to IMGT/mAb-DB
database logo
1417 entries
1234 -IG
7 -TR
47 -FPIA
68 -CPCA
61 -RPI

IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract PDF

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract PDF

IMGT/mAb-DB ID 829
INN apitegromab
INN Number 11471
INN Prop. List 123 (2020)
INN Rec. List 85 (2021)
Common name SRK-015, SRK015, SRK 015
Proprietary name
Species Homo sapiens
IMGT receptor type IG
Format (legend)
Receptor identification IgG4 - lambda
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB 11471
Specificity target name and species pro-MSTN (pro-growth differentiation factor 8, pro-GDF8, pro-myostatin, pro-GDF-8) [Homo sapiens]
Development Technology
Origin clone species
Origin clone name

Company Scholar Rock (Cambridge MA USA)
Expression system CHO (Chinese Hamster Ovary) cells
Application Therapeutic
Clinical domain Genetic disorder
Mechanism of action
Clinical indication Spinal muscular atrophy (SMA)
Development status Phase II
Regulatory agency status and year

Clinical trials
Authority decisions
    External links
      Format legend:

      © Copyright 1995-2023 IMGT®, the international ImMunoGeneTics information system® | Terms of use | About us | Contact us | Citing IMGT
      European Commission umontpellier CNRS